Abstract:Objective To analyze the correlation between the levels of squamous cell carcinoma antigen (SCCAg) and the clinicopathological characteristics of patients with cervical squamous carcinoma. To study the relationship of serum SCCAg levels of patients with recurrent cervical squamous carcinoma and disease prognosis and to investigate the survival rate of patients with recurrent cervical squamous carcinoma. Method ELISA method was used to determine the serum SCCAg levels for the patients, which included 300 cases before treatment and 500 cases after treatment. Results (1) Single factor analysis indicated that, before the treatment, the serum SCCAg levels were closely related to clinical stages, lymphatic metastasis, and deep myometrial invasion (t=3.01, P<0.05; t=6.81, P<0.001; t=3.01, P<0.05; respectively). However, they were not related to patient′s age, vascular embolization and tumor growth type (t=0.77, t=1.12, t=1.06; respectively, all P>0.05). Multifactor logistic regression analysis showed that the pretreatment SCCAg levels of patients were related to clinical stages, cavum pelvis lymphatic metastasis and myometrial invasion (χ2=2.88, P=0.0084; χ2=2.612, P=0.0156; χ2=2.570, P=0.0171; respectively). (2) Overall, recurrent disease developed in 180 of the 500 patients with cervical squamous carcinoma. One hundred and sixtyone recurrent patients showed elevated SCCAg levels (161/180, 89.4%). For the 60 patients who showed elevated SCCAg levels without any clinical symptoms as well as no sign of tumors by iconography, the median time for signs of elevating levels of serum SCCAg was 2.3 months. The longest time range was 150d between the increasing levels of the tumor markers and the appearance of the imaging features of pachygyria while the patients condition was going on. The 160 patients out of the 180 cases with recurrent cervical squamous carcinoma who were followed up had a median survival time of 9 months, with an average of 20 months. The total 3 year survival rate and 5 year survival rate was respectively 23.4% and 17.8%. (3) Single factor analysis indicated that recurrent patients' clinical stages, recurrent region and recurrent post treatment SCCAg levels were closely related with patients′ survival time (χ2=10.26, P<0.005; χ2=14.65, P<0.005; χ2=8.97, P<0.01; respectively). There was no statistical difference between the survival rate of recurrent patients with increased SCCAg level and patients without increased SCCAg levels (χ2=0.89, P>0.05）. Multiple factor analysis indicated that the clinical stages, recurrent post treatment SCCAg levels of patients with recurrence were independent prognostic factors (χ2=10.3372, P=0.0013; χ2=4.3889, P=0.0362; respectively). Conclusion The pretreatment SCCAg levels are closely related to patients' clinical stages, cavum pelvis lymphatic metastasis and deep myometrial invasion. Serum SCCAg levels are important for the advanced detection of cervical squamous carcinoma recurrence and prognosis prediction.

Key words:Uterine cervical neoplasms,Neoplasms,squamous cell,Prognosis,Squamous cell carcinoma antigen